Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial

Open access
Kreimer, Aimée R, Sampson, Joshua N, Porras, Carolina, Schiller, John T, Kemp, Troy, Herrero, Rolando, Wagner, Sarah, Boland, Joseph, Schussler, John, Lowy, Douglas R, Chanock, Stephen, Roberson, David, Sierra, Mónica S, Tsang, Sabrina H, Schiffman, Mark, Rodriguez, Ana Cecilia, Cortes, Bernal, Gail, Mitchell H, Hildesheim, Allan, Gonzalez, Paula, Pinto, Ligia A, for the Costa Rica HPV Vaccine Trial (CVT) Group·2020·JNCI: Journal of the National Cancer Institute

Abstract

Background: The authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of the bivalent HPV vaccine compared with women who received multiple doses and unvaccinated women. Methods: HPV infections were compared between HPV16 or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448). Results: Median follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9–11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers. Conclusion: More than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djaa011

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 211

Metadata

Authors
Kreimer, A. R., Sampson, J. N., Porras, C., Schiller, J. T., Kemp, T., Herrero, R., Wagner, S., Boland, J., Schussler, J., Lowy, D. R., Chanock, S., Roberson, D., Sierra, M. S., Tsang, S. H., Schiffman, M., Rodriguez, A. C., Cortes, B., Gail, M. H., Hildesheim, A., Gonzalez, P., Pinto, L. A., & for the Costa Rica HPV Vaccine Trial (CVT) Group
Venue
JNCI: Journal of the National Cancer Institute
Published
2020-02-10
Volume
112
Issue
10
Pages
1038-1046
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W3008661842
Cited by
211
References
4
FWCI
13.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. https://app.cochat.ai/papers/10.1093/jnci/djaa011
The paper
Kreimer, A. R., Sampson, J. N., Porras, C., Schiller, J. T., Kemp, T., Herrero, R., Wagner, S., Boland, J., Schussler, J., Lowy, D. R., Chanock, S., Roberson, D., Sierra, M. S., Tsang, S. H., Schiffman, M., Rodriguez, A. C., Cortes, B., Gail, M. H., Hildesheim, A., . . . for the Costa Rica HPV Vaccine Trial (CVT) Group. (2020). Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaa011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.